Behcet's Disease Uveitis

被引:1
|
作者
Joubert, Morgane [1 ]
Desbois, Anne-Claire [1 ]
Domont, Fanny [1 ]
Ghembaza, Amine [1 ]
Le Joncour, Alexandre [1 ]
Mirouse, Adrien [1 ]
Maalouf, Georgina [1 ]
Leclercq, Mathilde [2 ]
Touhami, Sarah [3 ]
Cacoub, Patrice [1 ]
Bodaghi, Bahram [3 ]
Saadoun, David [1 ,4 ]
机构
[1] AP HP, Ctr Reference Malad Autoimmunes Syst Rares, Ctr Reference Maladies Autoinflammat & Amylose Inf, F-75013 Paris, France
[2] CHU Rouen, Internal Med Dept, F-76000 Rouen, France
[3] Sorbonne Univ, Pitie Salpetriere Univ Hosp, Dept Ophthalmol, F-75013 Paris, France
[4] Inst Natl Sante & Rech Med INSERM, Unite Med Rech UMRS 59, F-75013 Paris, France
关键词
Behcet's disease; uveitis; vasculitis; biotherapies; anti TNF-alpha agents; LONG-TERM EFFICACY; NECROSIS FACTOR-ALPHA; REFRACTORY UVEITIS; INTERFERON-ALPHA; INTRAVITREAL INFLIXIMAB; OCULAR MANIFESTATIONS; NONINFECTIOUS UVEITIS; CYCLOSPORINE-A; REMISSION INDUCTION; ADALIMUMAB THERAPY;
D O I
10.3390/jcm12113648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Uveitis in Behcet's disease (BD) is frequent (40% of cases) and is a major cause of morbidity. The age of onset of uveitis is between 20 and 30 years. Ocular involvement includes anterior, posterior, or panuveitis. Uveitis may be the first sign of the disease in 20% of cases or it may appear 2 or 3 years after the first symptoms. Panuveitis is the most common presentation and is more commonly found in men. Bilateralization usually occurs on average 2 years after the first symptoms. The estimated risk of blindness at 5 years is 10-15%. BD uveitis has several ophthalmological features that distinguish it from other uveitis. The main goals in the management of patients are the rapid resolution of intraocular inflammation, the prevention of recurrent attacks, the achievement of complete remission, and the preservation of vision. Biologic therapies have changed the management of intraocular inflammation. The aim of this review is to provide an update to a previous article by our team on pathogenesis, diagnostic approaches, and the therapeutic strategy of BD uveitis.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Behcet's disease uveitis
    Joubert, M.
    Desbois, A. -C.
    Domont, F.
    Ghembaza, A.
    Lejoncour, A.
    Mirouse, A.
    Maalouf, G.
    Leclercq, M.
    Touhami, S.
    Cacoub, P.
    Bodaghi, B.
    Saadoun, D.
    REVUE DE MEDECINE INTERNE, 2023, 44 (10): : 546 - 554
  • [2] Behcet's Disease with Uveitis in Taiwan
    Chung, Yu-Mei
    Lin, Ying-Cheng
    Tsai, Chia-Chen
    Huang, De-Feng
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2008, 71 (10) : 509 - 516
  • [3] Uveitis associated with Behcet's disease
    Saadoun, D.
    Bodaghi, B.
    REVUE DE MEDECINE INTERNE, 2022, 43 : A277 - A286
  • [4] Azathioprine in Severe Uveitis of Behcet's Disease
    Saadoun, D.
    Wechsler, B.
    Terrada, C.
    Hajage, D.
    Huong, D. Le Thi
    Resche-Rigon, M.
    Cassoux, N.
    Le Hoang, P.
    Amoura, Z.
    Bodaghi, B.
    Cacoub, P.
    ARTHRITIS CARE & RESEARCH, 2010, 62 (12) : 1733 - 1738
  • [5] Effect of infliximab on refractory uveitis in Behcet's disease
    Sayarlioglu, M
    Cinal, A
    Topcu, N
    Demirok, A
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) : 901 - 902
  • [6] Gender Differences in Behcet's Disease Associated Uveitis
    Ucar-Comlekoglu, Didar
    Fox, Austin
    Sen, H. Nida
    JOURNAL OF OPHTHALMOLOGY, 2014, 2014
  • [7] INTERFERON ALPHA FOR TREATMENT OF UVEITIS IN BEHCET'S DISEASE
    Dubey, Rahul
    Wakefield, Dennis
    McCluskey, Peter
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 39 : 39 - 39
  • [8] Infliximab in refractory uveitis due to Behcet's disease
    Wechsler, B
    Sablé-Fourtassou, R
    Bodaghi, B
    Huong, DLT
    Cassoux, N
    Badelon, I
    Fain, O
    LeHoang, P
    Piette, JC
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (04) : S14 - S16
  • [9] Plasma homocysteine level and uveitis in Behcet's disease
    Okka, M
    Öztürk, M
    Korkar, MC
    Bavbek, N
    Rasier, Y
    Gunduz, K
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (11): : 931 - 934
  • [10] INFLIXIMAB TREATMENT FOR UVEITIS IN PATIENTS WITH BEHCET'S DISEASE
    Uehara, Takeaki
    Takeno, Mitsuhiro
    Hama, Maasa
    Omura, Kenji
    Suda, Akiko
    Ihata, Atsushi
    Ueda, Atsuhisa
    Ishigatsubo, Yoshiaki
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S123 - S123